5 completed, 1 not yet recruiting. 2 Phase 1, 2 Phase 4, 1 Not applicable, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 4 | 2 | Completed 2 |
| Not applicable | 1 | Not yet recruiting 1 |
| Phase 2 | 1 | Completed 1 |
Follow Opiate-Related Disorders: new trials by email Literature Review of Opiate-Related Disorders trials Research Report on Opiate-Related Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MedSMA℞T Mobile ED MedSMA℞T Mobile - Opiate-Related Disorders, Opiate Use Disorder | Not applicable | Not yet recruiting | Olufunmilola Abraham | 244 | 2027-08-01 | 2026-10-09 |
| A Chatbot To Support Substance Use Recovery chatbot - Opiate-Related Disorders, Opiate Substitution Treatment | Phase 1 / Phase 2 | Completed | Dimagi Inc. | 55 | 2025-03-07 | 2026-07-27 |
| Preference for Subutex® (Buprenorphine) Versus Suboxone® (Buprenorphine/Naloxone) in Opioid Dependent Patients on Subutex® (Study P05094)(COMPLETED) buprenorphine, buprenorphine/naloxone - Opiate-related Disorders, Opiate Dependence | Phase 4 | Completed | Indivior Inc. | 60 | 2007-07-01 | 2023-03-20 |
| Observational Study of Misuse of High Dose Buprenorphine (Subutex® or Generic) in Opiate-Addicted Patients in France (Study P05186AM1)(COMPLETED) buprenorphine - Buprenorphine, Naloxone | Completed | Indivior Inc. | 1307 | 2007-05-01 | 2023-03-20 | |
| Starting Treatment With Agonist Replacement Therapies (START) Buprenorphine/naloxone, Methadone - Opiate-related Disorders | Phase 4 | Completed | University of California, Los Angeles | 1269 | 2006-04-01 | 2017-01-06 |
| Treatment of Heroin and Cocaine With Methadone Maintenance and Contingency Management Methadone, Contingency Management, Methadone dose - Opiate-Related Disorders, Cocaine-Related Disorders | Phase 1 | Completed | National Institute on Drug Abuse (NIDA) | 140 | 2004-02-01 | 2019-12-17 |
Opioid-Related Disorders (3) · Substance-Related Disorders (2) · Cocaine-Related Disorders (1)
Chemically-Induced Disorders (4) · Mental Disorders (4) · Narcotic-Related Disorders (3) · Substance-Related Disorders (2)
Buprenorphine (2) · Buprenorphine, Naloxone Drug Combination (2) · Methadone (2) · Drugs, Generic (1)
Indivior Inc. (2) · Dimagi Inc. (1) · National Institute on Drug Abuse (NIDA) (1) · Olufunmilola Abraham (1) · University of California, Los Angeles (1)
United States (4)
Andrew Saxon, M.D. (1) · Jonathan Jackson, MEng (1) · Kenzie Preston, Ph.D. (1) · Olufunmilola Abraham, PhD (1) · Walter Ling, M.D. (1) · Y. Xian Ho, PhD (1)
PMID 22921476, PMID 23961726, PMID 24751432, PMID 29333880, PMID 34328394, PMID 36063082, PMID 36655851, PMID 38616571
R44DA050218 (1), U10DA013045 (1)